Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hb3 F(ab')2 is a divalent antibody fragment derived from the Hb3 sheep monoclonal antibody, specifically developed for the treatment of envenomation by the European adder (*Vipera berus*). It is produced by the enzymatic digestion of whole IgG molecules obtained from sheep immunized with *Vipera berus* venom, followed by affinity purification. The F(ab')2 fragment contains two antigen-binding sites but lacks the Fc region, which reduces the risk of certain adverse immune reactions while maintaining a higher molecular weight than monovalent Fab fragments. This increased size results in a longer half-life in the systemic circulation, potentially offering better protection against the delayed absorption or recurrence of venom toxins. Its primary mechanism is the high-affinity binding and neutralization of venom components, including phospholipase A2 and other toxic proteins.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hb3 F(ab')2.